Security key
252828108
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH)
CUSIP: 252828108
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 37,715,319
- Total 13F value
- $685,461,303
- Share change
- +2,591,437
- Put/Call ratio
- 202%
- SEC-reported price per share
- $18.14
- Number of holders
- 97
- Value change
- +$43,246,773
- Number of buys
- 43
- Number of sells
- 42
- Shares outstanding
- 54,411,104
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q1 2025
Institutions
97
Top holders
10
DNTH full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Dianthus Therapeutics, Inc. /DE/ SEC filings
Dianthus Therapeutics, Inc. /DE/ company facts
Broader feeds
Reporting periods
Holder history for CUSIP 252828108
Recent filing periods:
Ownership snapshot
Top reported holders of DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TCG Crossover GP II, LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
3/4/5
Lead comparable stake: 4.7%
13D/G row: TCG Crossover GP II, LLC
Showing 1-6 of 15 holder rows.
Quick read
TCG Crossover GP II, LLC leads the comparable SEC ownership view at 4.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
TCG Crossover GP II, LLC
4.7%
FMR LLC
8.2%
Avidity Partners Management LP
5.3%
Fairmount Funds Management LLC
5%
Bain Capital Life Sciences Invest...
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TCG Crossover GP II, LLC |
13D/G
|
4.7%
|
$32,660,322
1,501,624 shares
|
$0 | 31 Mar 2025 |
| FMR LLC |
13F
Company
|
8.2%
|
$96,776,325
4,439,281 shares
|
— | 31 Dec 2024 |
| Avidity Partners Management LP |
13F
Company
|
5.3%
|
$62,631,400
2,873,000 shares
|
— | 31 Dec 2024 |
| Fairmount Funds Management LLC |
13F
3/4/5
Company · Director
|
5%
|
$58,875,064
2,700,691 shares
|
— | 31 Dec 2024 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
4.9%
|
$58,635,613
2,689,707 shares
|
— | 31 Dec 2024 |
| Octagon Capital Advisors LP |
13F
Company
|
3.9%
|
$46,001,641
2,110,167 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
97
Shares
37,715,319
Rows available
97
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
94
Q1 2025 holders
97
Holder diff
3
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend